The principle of synthetic lethality, which refers to the loss of viability resulting from the disruption of two genes, which, individually, do not cause lethality This principle is primarily used to treat advanced ovarian and breast cancers associated with BRCA1 or BRCA2 gene mutations (74). Here, BRCA2 is linked to breast carcinoma.